This finding further supports the hypothesis that CD39 is involved in the pathogenesis of CLL and may explain why the abundance of CD39 in CLL patients does not produce a more dramatic reduction of the platelet response in this patient population. This evidence concerns the gene ENTPD1 and B-cell chronic lymphocytic leukemia.